<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761446</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMD 1330040</org_study_id>
    <nct_id>NCT03761446</nct_id>
  </id_info>
  <brief_title>The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults</brief_title>
  <acronym>REST</acronym>
  <official_title>The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To gather data on the impact of type 2 diabetes on muscle mass atrophy during a period of bed
      rest and recovery of muscle mass, strength, and physical function following bed rest.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leg Lean Mass</measure>
    <time_frame>3 days</time_frame>
    <description>DXA (dual energy x-ray absorptiometry) scans. Whole body and regional (including leg) fat and lean mass will be measured on a latest generation GE (General Electric) lunar iDXA.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Older adults with Type 2 Diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI-, age- and sex-matched non-diabetic controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bed rest intervention</intervention_name>
    <description>The participant will remain in bed rest for 10 complete days (240 hours).</description>
    <arm_group_label>BMI-, age- and sex-matched non-diabetic controls</arm_group_label>
    <arm_group_label>Older adults with Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test (OGTT)</intervention_name>
    <description>For nondiabetics ONLY. This test will be done to measure participant body's response to glucose (sugar)</description>
    <arm_group_label>BMI-, age- and sex-matched non-diabetic controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VO2max Test</intervention_name>
    <description>Aerobic fitness level will be assessed while participants pedals on a stationary bicycle.</description>
    <arm_group_label>BMI-, age- and sex-matched non-diabetic controls</arm_group_label>
    <arm_group_label>Older adults with Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Activity Monitor</intervention_name>
    <description>An activity monitor placed around your left upper arm and will be asked to wear the monitor for 7 days, except while showering/bathing. It is a tri-axial accelerometer that measures participant activity and uses those values to estimate the number of calories participants burn based on height, weight, age and gender.</description>
    <arm_group_label>BMI-, age- and sex-matched non-diabetic controls</arm_group_label>
    <arm_group_label>Older adults with Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging- IMAT</intervention_name>
    <description>Intermuscular adipose tissue (IMAT) is the fat that exists between muscle. This test will determine the amount of this type of fat inside thigh muscle.</description>
    <arm_group_label>BMI-, age- and sex-matched non-diabetic controls</arm_group_label>
    <arm_group_label>Older adults with Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biodex Strength Testing</intervention_name>
    <description>Leg strength will be measured using a Biodex machine. This testing is completed in a seated position on the machine and participants will extend and flex their leg against different resistance levels.</description>
    <arm_group_label>BMI-, age- and sex-matched non-diabetic controls</arm_group_label>
    <arm_group_label>Older adults with Type 2 Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant is a male or a non-pregnant, non-lactating female, at least 6 weeks
             postpartum prior to screening visit.

          2. Participant is 65 to 80 years of age.

          3. Participant has type 2 diabetes and is only taking (dipeptidyl-peptidase) DPP-4
             inhibitors, Sulfonylureas and/or Metformin therapy (but not Insulin, injectable
             incretin mimetics and Thiazolidinedione's), and has an A1C &lt; 7.5%.

          4. Participant has normal renal function: estimated glomerular filtration rate (eGFR) &gt;
             50 ml/min/1.73m2 determined at screening.

          5. Participant's triglyceride level is &lt; 250 mg/dl and LDL cholesterol is ≤ 150 mg/dl at
             screening.

          6. Participant has a urine albumin-to-creatinine ratio (UACR) &lt; 300 mg/g at screening in
             a single urine specimen (per National Kidney Foundation guideline).

          7. Participant states willingness to follow protocol as described, including consumption
             of study product per protocol, the prescribed activity level and completing any forms
             needed throughout the study.

          8. Participant has voluntarily signed and dated an informed consent form, approved by an
             Institutional Review Board/Independent Ethics Committee, and provided Health Insurance
             Portability and Accountability Act authorization (HIPAA) or other privacy
             authorization prior to any participation in study.

        Exclusion Criteria:

          1. Participant has type 1 Diabetes.

          2. Participant is actively pursuing weight loss and/or lifestyle changes.

          3. Participant has a history of pressure ulcers.

          4. Participant has a stated history of Deep Vein Thrombosis (DVT), recent (within last 3
             months) pulmonary embolism, or has a positive D-dimer test and lower extremity
             ultrasound at screening, or a known hypercoagulable condition, or other clotting or
             bleeding disorders.

          5. Participant has poorly controlled hypertension or hypotension in the opinion of the
             study PI.

          6. Participant has untreated hypothyroidism or hyperthyroidism.

          7. Participant has current infection (requiring prescription antimicrobial or antiviral
             medication, or hospitalization), or corticosteroid treatment (with the exception of
             inhaled or topical steroids) in the last 3 months prior to screening visit.

          8. Participant is currently taking prescription strength anti-inflammatory medication, or
             has taken prescription strength anti-inflammatory medication in the 6 weeks prior to
             screening.

          9. Participant has had surgery requiring &gt; 2 days of hospitalization in the last 3 weeks
             prior to screening visit.

         10. Participant has an active malignancy or autoimmune disease.

         11. Participant has current significantly impaired liver function in the opinion of the
             study PI (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥
             2.5 times normal limit.

         12. Participant has a chronic, contagious, infectious disease, such as active
             tuberculosis, Hepatitis B or C, or HIV.

         13. Participant is an amputee and/or has presence of partial or full artificial limb.

         14. Participant has had a significant cardiovascular event (e.g. myocardial infarction,
             stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart
             failure; or participant has evidence of cardiovascular disease assessed during the EKG
             at screening. In the event of a positive stress test, participants are referred to
             their primary care physician. If the electrocardiogram (ECGEKG) is determined to be a
             false negative, participant may be allowed to participate in study.

         15. Participant has a history of, or currently has uncontrolled severe diarrhea, nausea or
             vomiting.

         16. Participant has an obstruction of the gastrointestinal tract, inflammatory bowel
             disease, short bowel syndrome or other forms of gastrointestinal disease such as stage
             III or above gastroesophageal reflux disease, gastroparesis, peptic ulcer disease,
             celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis.

         17. Participant cannot abstain from alcohol for the pre bed rest and bed rest portion of
             the study. For the recovery portion of the study the participant must agree to consume
             no more than 1 glass of wine (4-5 oz) or bottle of beer (12 oz) /day.

         18. Participant cannot refrain from taking medications/dietary supplements/herbals or
             substances that could modulate glucose metabolism (other than oral hypoglycemic
             medications), or are considered anabolic, or reduce weight (fat mass) in the opinion
             of the PI or medical provider, starting two weeks prior to enrollment and over the
             entire course of the study. These include progestational agents (except prescribed
             birth control), steroids, growth hormone, dronabinol, marijuana,
             calcium-beta-hydroxy-betamethylbutyrate (CaHMB), free amino acid supplements and
             dietary supplements to aid weight loss.

         19. Participant has a mini-Mental State Examination score &lt; 21.

         20. Subjects who fulfill any of the contraindications for MRI; examples include metal
             implants, devices, paramagnetic objects contained within the body and excessive or
             metal-containing tattoos

         21. Unable to participate in magnetic resonance (MR) or Dual-energy X-ray absorptiometry
             (DEXA) assessments due to physical limitations of equipment tolerances (e.g., MRI bore
             size and DEXA 450-pound weight limit) based on Investigator's judgment at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Coen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Research Institute for Metabolism and Diabetes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>tri@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>tri@flhosp.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org/</url>
    <description>Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>DEITRICK JE. The effect of immobilization on metabolic and physiological functions of normal men. Bull N Y Acad Med. 1948 Jun;24(6):364-75.</citation>
    <PMID>18860463</PMID>
  </reference>
  <reference>
    <citation>Gibson JN, Halliday D, Morrison WL, Stoward PJ, Hornsby GA, Watt PW, Murdoch G, Rennie MJ. Decrease in human quadriceps muscle protein turnover consequent upon leg immobilization. Clin Sci (Lond). 1987 Apr;72(4):503-9.</citation>
    <PMID>2435445</PMID>
  </reference>
  <reference>
    <citation>LeBlanc AD, Schneider VS, Evans HJ, Pientok C, Rowe R, Spector E. Regional changes in muscle mass following 17 weeks of bed rest. J Appl Physiol (1985). 1992 Nov;73(5):2172-8.</citation>
    <PMID>1474100</PMID>
  </reference>
  <reference>
    <citation>DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. Natl Health Stat Report. 2008 Jul 30;(5):1-20.</citation>
    <PMID>18841653</PMID>
  </reference>
  <reference>
    <citation>Fisher SR, Kuo YF, Graham JE, Ottenbacher KJ, Ostir GV. Early ambulation and length of stay in older adults hospitalized for acute illness. Arch Intern Med. 2010 Nov 22;170(21):1942-3. doi: 10.1001/archinternmed.2010.422.</citation>
    <PMID>21098357</PMID>
  </reference>
  <reference>
    <citation>Paddon-Jones D, Sheffield-Moore M, Urban RJ, Sanford AP, Aarsland A, Wolfe RR, Ferrando AA. Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bedrest. J Clin Endocrinol Metab. 2004 Sep;89(9):4351-8.</citation>
    <PMID>15356032</PMID>
  </reference>
  <reference>
    <citation>Suetta C, Hvid LG, Justesen L, Christensen U, Neergaard K, Simonsen L, Ortenblad N, Magnusson SP, Kjaer M, Aagaard P. Effects of aging on human skeletal muscle after immobilization and retraining. J Appl Physiol (1985). 2009 Oct;107(4):1172-80. doi: 10.1152/japplphysiol.00290.2009. Epub 2009 Aug 6.</citation>
    <PMID>19661454</PMID>
  </reference>
  <reference>
    <citation>Hvid L, Aagaard P, Justesen L, Bayer ML, Andersen JL, Ørtenblad N, Kjaer M, Suetta C. Effects of aging on muscle mechanical function and muscle fiber morphology during short-term immobilization and subsequent retraining. J Appl Physiol (1985). 2010 Dec;109(6):1628-34. doi: 10.1152/japplphysiol.00637.2010. Epub 2010 Sep 23.</citation>
    <PMID>20864557</PMID>
  </reference>
  <reference>
    <citation>Suetta C, Frandsen U, Mackey AL, Jensen L, Hvid LG, Bayer ML, Petersson SJ, Schrøder HD, Andersen JL, Aagaard P, Schjerling P, Kjaer M. Ageing is associated with diminished muscle re-growth and myogenic precursor cell expansion early after immobility-induced atrophy in human skeletal muscle. J Physiol. 2013 Aug 1;591(15):3789-804. doi: 10.1113/jphysiol.2013.257121. Epub 2013 Jun 3.</citation>
    <PMID>23732643</PMID>
  </reference>
  <reference>
    <citation>Covinsky KE, Palmer RM, Fortinsky RH, Counsell SR, Stewart AL, Kresevic D, Burant CJ, Landefeld CS. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003 Apr;51(4):451-8.</citation>
    <PMID>12657063</PMID>
  </reference>
  <reference>
    <citation>Coker RH, Hays NP, Williams RH, Wolfe RR, Evans WJ. Bed rest promotes reductions in walking speed, functional parameters, and aerobic fitness in older, healthy adults. J Gerontol A Biol Sci Med Sci. 2015 Jan;70(1):91-6. doi: 10.1093/gerona/glu123. Epub 2014 Aug 13.</citation>
    <PMID>25122628</PMID>
  </reference>
  <reference>
    <citation>Fortinsky RH, Covinsky KE, Palmer RM, Landefeld CS. Effects of functional status changes before and during hospitalization on nursing home admission of older adults. J Gerontol A Biol Sci Med Sci. 1999 Oct;54(10):M521-6.</citation>
    <PMID>10568535</PMID>
  </reference>
  <reference>
    <citation>Mithal A, Bonjour JP, Boonen S, Burckhardt P, Degens H, El Hajj Fuleihan G, Josse R, Lips P, Morales Torres J, Rizzoli R, Yoshimura N, Wahl DA, Cooper C, Dawson-Hughes B; IOF CSA Nutrition Working Group. Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int. 2013 May;24(5):1555-66. doi: 10.1007/s00198-012-2236-y. Epub 2012 Dec 18. Review. Erratum in: Osteoporos Int. 2013 Apr;24(4):1527-8.</citation>
    <PMID>23247327</PMID>
  </reference>
  <reference>
    <citation>Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Cho YW, Newman AB; Health, Aging, and Body Composition Study. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007 Jun;30(6):1507-12. Epub 2007 Mar 15.</citation>
    <PMID>17363749</PMID>
  </reference>
  <reference>
    <citation>Miller DK, Lui LY, Perry HM 3rd, Kaiser FE, Morley JE. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol A Biol Sci Med Sci. 1999 May;54(5):M230-6.</citation>
    <PMID>10362005</PMID>
  </reference>
  <reference>
    <citation>De Rekeneire N, Resnick HE, Schwartz AV, Shorr RI, Kuller LH, Simonsick EM, Vellas B, Harris TB; Health, Aging, and Body Composition study. Diabetes is associated with subclinical functional limitation in nondisabled older individuals: the Health, Aging, and Body Composition study. Diabetes Care. 2003 Dec;26(12):3257-63.</citation>
    <PMID>14633811</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03761446/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

